NCT04892017 2026-04-08Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid TumorsDeciphera Pharmaceuticals, LLCPhase 1 Terminated91 enrolled
NCT04657991 2026-04-07A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic MelanomaPfizerPhase 3 Active not recruiting257 enrolled
NCT05203172 2026-04-07The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical TrialsPfizerPhase 4 Recruiting46 enrolled
NCT05355701 2026-03-27A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.PfizerPhase 1 Recruiting267 enrolled
NCT03915951 2026-03-24An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung CancerPfizerPhase 2 Completed98 enrolled 18 charts 2 FDA
NCT03947385 2026-01-27Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC FusionsIDEAYA BiosciencesPhase 1/2 Recruiting336 enrolled
NCT04585815 2026-01-09Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)PfizerPhase 1/2 Terminated34 enrolled 44 charts
NCT04913285 2025-12-24A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid TumorsPierre Fabre MedicamentPhase 1 Active not recruiting400 enrolled
NCT04543188 2025-10-23A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain InvolvementPfizerPhase 1 Terminated65 enrolled 52 charts